JNJ-40418677(JNJ-40418677) - 药物靶点：γ-secretase_在研适应症：阿尔茨海默症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

γ-secretase

作用机制

γ-secretase调节剂(γ-分泌酶复合体调节剂)

治疗领域

神经系统疾病

在研适应症

阿尔茨海默症

非在研适应症-

原研机构

Janssen Pharmaceutical Unlimited Co.

在研机构

Janssen Pharmaceutical Unlimited Co.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C26H22F6O2

InChIKeyRQOWDDLKGBMJFX-QHCPKHFHSA-N

CAS号1146594-87-7

关联

100 项与 JNJ-40418677 相关的临床结果

登录后查看更多信息

100 项与 JNJ-40418677 相关的转化医学

登录后查看更多信息

100 项与 JNJ-40418677 相关的专利（医药）

登录后查看更多信息

1

项与 JNJ-40418677 相关的文献（医药）

2024-07-01·SLAS Discovery

A high-throughput cell-based screening method for Zika virus protease inhibitor discovery

Article

作者: Ngo, Khac Huy ; Lattmann, Simon ; Scampavia, Louis ; Otsuka, Yuka ; Liew, Chong Wai ; Kang, CongBao ; Anindita, Paulina Duhita ; Luo, Dahai ; Harris, Reuben S ; Spicer, Timothy P

Zika virus (ZIKV) continues to pose a significant global public health threat, with recurring regional outbreaks and potential for pandemic spread. Despite often being asymptomatic, ZIKV infections can have severe consequences, including neurological disorders and congenital abnormalities. Unfortunately, there are currently no approved vaccines or antiviral drugs for the prevention or treatment of ZIKV. One promising target for drug development is the ZIKV NS2B-NS3 protease due to its crucial role in the virus life cycle. In this study, we established a cell-based ZIKV protease inhibition assay designed for high-throughput screening (HTS). Our assay relies on the ZIKV protease's ability to cleave a cyclised firefly luciferase fused to a natural cleavage sequence between NS2B and NS3 protease within living cells. We evaluated the performance of our assay in HTS setting using the pharmacologic controls (JNJ-40418677 and MK-591) and by screening a Library of Pharmacologically Active Compounds (LOPAC). The results confirmed the feasibility of our assay for compound library screening to identify potential ZIKV protease inhibitors.

100 项与 JNJ-40418677 相关的药物交易

登录后查看更多信息